Alan Katz came through again with a 10-year SBRT update. This one is only on his low risk patients (intermediate and high risk update will be presented at next year's ASTRO meeting). This makes it the longest follow-up study on any kind of external beam radiation for PC. It ties with the MSK study of IMRT, but with much bigger sample size.
For the low risk men, SBRT did better than IMRT in oncological control, and the same on side effects.
I can't imagine any insurance company now saying that longer follow-up is needed.
/pcnrv.blogspot.com/2017/09/record-10-year-sbrt-study-among-low.html